"We exist to make a difference for the better and these are important times to do just that."
The Company expects to have a conference call on Tuesday, March 10, 2009.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and immune diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
NOTE: Other than statements of historical fact, the statements made in
this press release about projected operating expenses, future plans and
timelines for our preclinical studies and clinical trials, progress of and
reports of results from preclinical studies and clinical trials, clinical
development plans and product development and corporate partnering activities
are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. The words "project," "believe," "will," "may,"
"continue," "plan," "expect," "intend," "anticipate," variations of such
words, and similar expressions also identify forward-looking statements, but
their absence does not mean that the statement is not forward-looking. The
forward-looking statements are not guarantees of future performance an
|SOURCE Pharmacyclics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved